Randomized Multinational Double-Blind Placebo-Controlled Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, PK [pharmacokinetic] and PD [pharmacodynamic] Effects of Teriflunomide for 24 Weeks When Added to Interferon-beta in Subjects With Multiple Sclerosis.

Trial Profile

Randomized Multinational Double-Blind Placebo-Controlled Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, PK [pharmacokinetic] and PD [pharmacodynamic] Effects of Teriflunomide for 24 Weeks When Added to Interferon-beta in Subjects With Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2012

At a glance

  • Drugs Teriflunomide (Primary) ; Interferon beta
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jun 2010 One-year data from this study were the subject of the leading oral presentation at the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) 2010, according to a sanofi-aventis media release.
    • 11 Sep 2009 Results were presented at ECTRIMS 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top